Cinctive Capital Management LP Xenon Pharmaceuticals Inc. Transaction History

Cinctive Capital Management LP

  • $1.72 Billion
  • Q3 2024

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024
SELL
$36.25 - $43.75 $407,812 - $492,187
-11,250 Reduced 35.41%
20,520 $800,000
Q1 2024

May 15, 2024
BUY
$42.66 - $50.04 $177,892 - $208,666
4,170 Added 15.11%
31,770 $1.37 Million
Q4 2023

Feb 14, 2024
BUY
$28.7 - $46.46 $792,120 - $1.28 Million
27,600 New
27,600 $1.27 Million
Q2 2022

Aug 15, 2022
SELL
$25.44 - $35.16 $31,291 - $43,246
-1,230 Reduced 2.91%
41,073 $1.25 Million
Q4 2021

Feb 14, 2022
BUY
$15.6 - $35.4 $659,926 - $1.5 Million
42,303 New
42,303 $1.32 Million

Others Institutions Holding XENE

# of Institutions
212
Shares Held
70.2M
Call Options Held
88.3K
Put Options Held
28.8K
View Full List

About Xenon Pharmaceuticals Inc.

XENE Quotes by TradingView
  • Ticker XENE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 62,263,500
  • Market Cap $2.39B
  • Description
  • Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopath...
More about XENE
Track This Portfolio

Track Cinctive Capital Management LP Portfolio

Follow Cinctive Capital Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cinctive Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Cinctive Capital Management LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email